MindRhythm Announces Launch of the Company; Enrolls First Patient in Prehospital Trial on Stroke Triage

MindRhythm, a medical technology company focused on preventing neurological injury in stroke, today announced the enrollment of its first patient in a multicenter trial out of Wayne State University in partnership with Detroit Receiving Hospital, Henry Ford Hospital, Sinai-Grace Hospital, and Ascension St. John Hospital.

The intention is to demonstrate the effectiveness of MindRhythm’s proprietary technology in rapidly identifying patients with Large Vessel Occlusion (LVO) strokes prehospital for direct dispatch to a Comprehensive Stroke Center (CSC) hospital able to treat LVO stroke.

“We are incredibly excited to now be enrolling patients in the MindRhythm trial,” said Dr. James Paxton, Wayne State University. “MindRhythm’s technology has the potential to save lives and change the course of stroke triage. We plan to hit the ground running in order to validate the effectiveness of MindRhythm through the multicenter clinical trial to help reduce the severity of neurological injury caused by LVO strokes.”

Stroke is the fifth leading cause of death in the United States, and its most lethal form is termed Large Vessel Occlusion (LVO) stroke. However, there is no technology available to objectively diagnose LVO stroke in an EMS setting, often leading to delays in treatment. Further, relatively few hospitals in the U.S. possess the necessary equipment to effectively treat LVO strokes and need fully-trained critical care staffing to support the use and treatment of patients with this type of equipment. To date, EMS and paramedics don’t have the means to determine the type of stroke in their patients and therefore have trouble deciding if they should transport the patient to a CSC hospital able to treat LVO stroke.

“With this multicenter trial, MindRhythm is providing a new opportunity for hospitals and EMS to more easily identify and treat one of the most debilitating types of strokes,” said John Keane, President and CEO, MindRhythm. “We are proud to be working with some of the brightest minds in medicine to help solve one of medicine’s most critical problems.”

The enrollment of the first patient in the multicenter trial follows a successful, 64-person study completed at UC San Francisco and the publication of two peer-reviewed papers authored by MindRhythm co-founders Wade Smith, MD, PhD, Chair, Scientific Advisory Board and Paul Lovoi, PhD and CTO, alongside Kevin Keenan, MD, Vascular Neurologist to further demonstrate the efficacy of the HeadPulse measurement within the Harmony headset developed by MindRhythm.

A Unique Signature of Cardiac-Induced Cranial Forces During Acute Large Vessel Stroke and Development of a Predictive Model, published in October 2019, explores the cranial accelerometry technique in a cohort of code stroke patients to see whether a signature could be identified to aid in the diagnosis of LVO stroke. The second publication, The Neurological Examination Improves Cranial Accelerometry Large Vessel Occlusion Prediction Accuracy, published in November 2020, combined cranial accelerometry, a device-based approach to LVO prediction, with neurological examination findings to determine if this improves diagnostic accuracy compared to either alone.

MindRhythm, founded in 2019 by Keane, Smith, and Lovoi, also officially launched today as a medical technology company optimizing stroke triage in the prehospital and hospital settings. MindRhythm’s Harmony device is a novel, non-invasive, diagnostic medical device that can rapidly identify patients with LVO strokes via monitoring of a specific physiology discovered by UCSF and MindRhythm. Patients who use MindRhythm’s device can benefit from rapid transport to a Comprehensive Stroke Center (CSC) that has the physicians, technologists and equipment needed to remove the clot. MindRhythm’s finely-tuned, proprietary technology effectively triages patients, communicates patient data, and provides remote location status to hospital teams prior to arrival thus optimizing patient treatment and outcomes.

Hot this week

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”

Avery Dennison Medical Introduces Ipdated SilFoam Lite: Sustainability, MDR Certification & Performance Improvements

The newly enhanced SilFoam Lite delivers superior efficiency and reliability, bringing improved fluid handling capabilities and improved tack. These improvements make the product ideal for customers seeking quality, high-performance solutions in wound care notes Avery Dennison Medical.

Voluntary Recall Notifying Medtronic Insulin Pump Users of Potential Risks of Shortened Pump Battery Life

Medtronic plc voluntarily issued a field action starting on July 31, 2024, notifying global customers of its MiniMed™ 600 series or 700 series insulin pumps to follow their pump's built-in alerts and alarms for battery status and to contact Medtronic if they observe changes in the battery life of their pump

Medtronic Expands AiBLE Spine Surgery Ecosystem with New Technologies and Siemens Healthineers Partnership

New advancements in the AiBLE Spine Surgery ecosystem build upon the company's commitment to procedural innovation and execution